419557-33-8

Usage

Uses

Used in Pharmaceutical Applications:
2-(3-BROMO-PHENYL)-IMIDAZO[1,2-A]PYRIDINE is used as a chemical intermediate for the development of new drugs. Its unique structure and properties make it a valuable candidate for further research in medicinal chemistry and drug discovery.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-(3-BROMO-PHENYL)-IMIDAZO[1,2-A]PYRIDINE is used as a starting material for the synthesis of various bioactive compounds. Its heterocyclic nature and bromine substitution provide opportunities for further functionalization and optimization of drug candidates.
Used in Drug Discovery:
2-(3-BROMO-PHENYL)-IMIDAZO[1,2-A]PYRIDINE is utilized in drug discovery processes to identify potential therapeutic agents. Its unique structure allows for the exploration of novel mechanisms of action and the development of targeted treatments for various diseases and conditions.

Upstream product

• 274-76-0 imidazo[1,2-a]pyridine 
• 24280-05-5 N-[1-(3-bromophenyl)ethylidene]hydroxyl amine 

Downstream Products

• 1450625-63-4 ethyl 2-(3-bromophenyl)imidazo[1,2-a]pyridine-3-carboxylate 
• 881040-26-2 2-(3-bromophenyl)imidazo[1,2-a]pyridine-3-carbaldehyde 

Relevant academic research and scientific papers

CuCl2-catalyzed N[sbnd]O bond cleavage of oxime esters: Approach to imidazoheterocycles and furo[3,2-c]chromenyl fused imidazoles

An articulate approach to a diverse set of imidazoheterocycles in good to high yields via a copper-catalyzed aza-annulation of several oxime esters with a group of 2-amino-azaarenes was developed. The above cyclization reaction probably proceeds via a single electron transfer process which embodies a new technique for creating two new C[sbnd]N bonds for imidazole ring synthesis. Gratifyingly, the implementation of this chemistry could be further stretched to the synthesis of a novel class of fused imidazoles bearing a furo[3,2-c]chromene moiety via a sequential C[sbnd]N bond formation, followed by C(sp2)-H functionalization/5-endo-dig-oxacyclization (C[sbnd]C and C[sbnd]O bonds) of in situ produced fused imidazoles with cyclic enynones in the presence of copper(II) as a π-electrophilic Lewis acid catalyst.

Regioselective direct c-3 arylation of imidazo[1,2- a ]pyridines with aryl tosylates and mesylates promoted by palladium-phosphine complexes

Direct C-3 arylation of imidazo[1,2-a]pyridines with aryl tosylates and mesylates has been accomplished by employing palladium(II) acetate associated with SPhos (2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl) or L1 (2-(2-(diisopropylphosphino)phenyl)-1-methyl-1H-indole). This catalyst system can be applied to a wide range of aryl sulfonates and shows excellent C-3 regioselectivity of imidazo[1,2-a]pyridine. These results represent the first examples of using tosylate- and mesylate-functionalized arenes as the electrophile partners for this regioselective direct arylation.

IMIDAZOPYRIDINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT ELEMENTS CONTAINING SAME

An imidazopyridine derivative shown by the following formula (1).

Substituted imidazo[1,2-A] pyridine derivatives

The present invention is a series of novel compounds of formula I and a method of treatment or prevention of a mGluR5 receptor mediated disease by administering an therapeutically effective amount of a compound formula 1wherein R1 and R2 are selected from hydrogen, (C1-6)-alkyl, halogen, hydroxy, (C1-6)-alkoxy and A is defined the description, or a pharmaceutically acceptable salt thereof.